Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cusan

Showing results (71-80 of 136) with videos related to

Pageof 14
Sort By:
British Journal of Urology|June 1, 1989
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapyF Labrie, A Dupont, A Bélanger, et al.
The Journal of Steroid Biochemistry and Molecular Biology|January 1, 1991
Steroid glucuronides: human circulatory levels and formation by LNCaP cellsA Bélanger, M Brochu, D Lacoste, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 25, 2008
Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEAFernand Labrie, Leonello Cusan, Jose-Luis Gomez, et al.
Farmaco (Societa Chimica Italiana : 1989)|April 26, 2005
Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitorsClaudia Cusan, Giampiero Spalluto, Maurizio Prato, et al.
Current Drug Discovery Technologies|May 23, 2006
Anti-inflammatory and anti-oxidant activity of a new class of phenyl-pyrazolone derivativesC Cusan, G Altinier, S Sosa, et al.
Farmaco (Societa Chimica Italiana : 1989)|January 18, 2005
Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitorsClaudia Cusan, Giampiero Spalluto, Maurizio Prato, et al.
The Prostate|April 1, 1996
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapyT H Van der Kwast, B Têtu, Y Fradet, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1988
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamideS Moorjani, A Dupont, F Labrie, et al.
Cancer Surveys|January 1, 1995
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomyF Labrie, L Cusan, J L Gomez, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinomaA Dupont, F Labrie, M Giguere, et al.
Pageof 14

Showing results (71-80 of 136) with videos related to

Sort By:
Pageof 14
British Journal of Urology|June 1, 1989
Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapyF Labrie, A Dupont, A Bélanger, et al.
The Journal of Steroid Biochemistry and Molecular Biology|January 1, 1991
Steroid glucuronides: human circulatory levels and formation by LNCaP cellsA Bélanger, M Brochu, D Lacoste, et al.
The Journal of Steroid Biochemistry and Molecular Biology|March 25, 2008
Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEAFernand Labrie, Leonello Cusan, Jose-Luis Gomez, et al.
Farmaco (Societa Chimica Italiana : 1989)|April 26, 2005
Synthesis and biological evaluation of a new class of acyl derivatives of 3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitorsClaudia Cusan, Giampiero Spalluto, Maurizio Prato, et al.
Current Drug Discovery Technologies|May 23, 2006
Anti-inflammatory and anti-oxidant activity of a new class of phenyl-pyrazolone derivativesC Cusan, G Altinier, S Sosa, et al.
Farmaco (Societa Chimica Italiana : 1989)|January 18, 2005
Synthesis and biological evaluation of new phenidone analogues as potential dual cyclooxygenase (COX-1 and COX-2) and human lipoxygenase (5-LOX) inhibitorsClaudia Cusan, Giampiero Spalluto, Maurizio Prato, et al.
The Prostate|April 1, 1996
Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapyT H Van der Kwast, B Têtu, Y Fradet, et al.
The Journal of Clinical Endocrinology and Metabolism|February 1, 1988
Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamideS Moorjani, A Dupont, F Labrie, et al.
Cancer Surveys|January 1, 1995
Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomyF Labrie, L Cusan, J L Gomez, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinomaA Dupont, F Labrie, M Giguere, et al.
Pageof 14